Update on Mucin-1 immunotherapy in cancer: a clinical perspective

Bibliography

• Shimizu M, Yamauchi K. Isolation and characterization of mucin-like glycoprotein in human milk fat globule membrane. J Biochem 1982;91(2):515-24
   PubMed Web of Science ®Google Scholar
• Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010;29(20):2893-904
   PubMed Web of Science ®Google Scholar
• Wreschner DH, Hareuveni M, Tsarfaty I, et al. Human epithelial tumor antigen cDNA sequences. Differential splicing may generate multiple protein forms. Eur J Biochem 1990;189(3):463-73
   PubMedGoogle Scholar
• Lan MS, Batra SK, Qi W-N, et al. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem 1990;265(25):15294-9
   PubMed Web of Science ®Google Scholar
• Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265(25):15286-93
   PubMed Web of Science ®Google Scholar
• Ligtenberg MJ, Vos HL, Gennissen AM, Hilkens J. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 1990;265(10):5573-8
   PubMed Web of Science ®Google Scholar
• Linden SK, Sutton P, Karlsson NG, et al. Mucins in the mucosal barrier to infection. Mucosal Immunol 2008;1(3):183-97
   PubMed Web of Science ®Google Scholar
• McAuley JL, Linden SK, Png CW, et al. MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. J Clin Invest 2007;117(8):2313-24
   PubMed Web of Science ®Google Scholar
• Ligtenberg MJ, Kruijshaar L, Buijs F, et al. Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 1992;267(9):6171-7
   PubMed Web of Science ®Google Scholar
• Swallow DM, Gendler S, Griffiths B, et al. The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature 1987;328(6125):82-4
   PubMed Web of Science ®Google Scholar
• Hayes DF, Sekine H, Ohno T, et al. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 1985;75(5):1671-8
   PubMed Web of Science ®Google Scholar
• Parmley RR, Gendler SJ. Cystic fibrosis mice lacking Muc1 have reduced amounts of intestinal mucus. J Clin Invest 1998;102(10):1798-806
   PubMed Web of Science ®Google Scholar
• McGuckin MA, Every AL, Skene CD, et al. Muc1 mucin limits both Helicobacter pylori colonization of the murine gastric mucosa and associated gastritis. Gastroenterology 2007;133(4):1210-18
   PubMed Web of Science ®Google Scholar
• Zhang K, Baeckstrom D, Brevinge H, Hansson GC. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells. J Cell Biochem 1996;60(4):538-49
   PubMed Web of Science ®Google Scholar
• Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996;7(4):565-77
   PubMed Web of Science ®Google Scholar
• Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2013;32(9):1073-81
   PubMed Web of Science ®Google Scholar
• Zhang K, Sikut R, Hansson GC. A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell Immunol 1997;176(2):158-65
   PubMed Web of Science ®Google Scholar
• van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 1993;151(2):767-76
   PubMed Web of Science ®Google Scholar
• Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int Immunol 1998;10(12):1907-16
   PubMed Web of Science ®Google Scholar
• Mitchell PL, Battye S, John T, et al. Expression of Mucin 1 in non-small cell lung cancer: relationship between immunohistochemistry, tumor characteristics and survival. WCLC abstract 2765. J Thorac Oncol 2013;8(Suppl 2):S1091-S92
   Google Scholar
• Mitchell PL, Asadi K, John T, et al. Mucin 1 (MUC1) expression in patients with early stage non-small cell lung cancer: Relationship between immunohistochemistry and in primary tumour and soluble MUC1 level. (Abstract 57P). J Thorac Oncol 2014;9(Suppl 1):S25
   Google Scholar
• MacDermed DM, Khodarev NN, Pitroda SP, et al. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics 2010;3:16
   PubMed Web of Science ®Google Scholar
• Khodarev NN, Pitroda SP, Beckett MA, et al. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res 2009;69(7):2833-7
   PubMed Web of Science ®Google Scholar
• Baeckstrom D, Karlsson N, Hansson GC. Purification and characterization of sialyl-Le(a)-carrying mucins of human bile; evidence for the presence of MUC1 and MUC3 apoproteins. J Biol Chem 1994;269(20):14430-7
   PubMed Web of Science ®Google Scholar
• Lloyd KO, Burchell J, Kudryashov V, et al. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem 1996;271(52):33325-34
   PubMed Web of Science ®Google Scholar
• Burchell JM, Mungul A, Taylor-Papadimitriou J. O-linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia 2001;6(3):355-64
   PubMed Web of Science ®Google Scholar
• Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989;86(18):7159-63
   PubMed Web of Science ®Google Scholar
• Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007;26(12):1693-701
   PubMed Web of Science ®Google Scholar
• Huang L, Ren J, Chen D, et al. MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther 2003;2(6):702-6
   PubMed Web of Science ®Google Scholar
• Wei X, Xu H, Kufe D. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res 2007;67(4):1853-8
   PubMed Web of Science ®Google Scholar
• Yin L, Huang L, Kufe D. MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem 2004;279(44):45721-7
   PubMed Web of Science ®Google Scholar
• Ren J, Bharti A, Raina D, et al. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene 2006;25(1):20-31
   PubMed Web of Science ®Google Scholar
• Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 2004;279(20):20607-12
   PubMed Web of Science ®Google Scholar
• Agata N, Ahmad R, Kawano T, et al. MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res 2008;68(15):6136-44
   PubMed Web of Science ®Google Scholar
• Satoh S, Hinoda Y, Hayashi T, et al. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int J Cancer 2000;88(4):507-18
   PubMed Web of Science ®Google Scholar
• Regimbald LH, Pilarski LM, Longenecker BM, et al. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 1996;56(18):4244-9
   PubMed Web of Science ®Google Scholar
• Singh PK, Wen Y, Swanson BJ, et al. Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 2007;67(11):5201-10
   PubMed Web of Science ®Google Scholar
• Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 1993;151(3):1654-62
   PubMed Web of Science ®Google Scholar
• von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000;18(3):574-83
   PubMed Web of Science ®Google Scholar
• Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998;4(1):43-9
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(1):59-68
   PubMed Web of Science ®Google Scholar
• Mitchell P, Thatcher N, Socinski MA, et al. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol 2015;26(6):1134-42
   PubMed Web of Science ®Google Scholar
• Goydos JS, Elder E, Whiteside TL, et al. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996;63(1):298-304
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996;14(9):930-8
   PubMed Web of Science ®Google Scholar
• Karanikas V, Thynne G, Mitchell P, et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J Immunother 2001;24(2):172-83
   Web of Science ®Google Scholar
• Reddish M, MacLean GD, Koganty RR, et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 1998;76(6):817-23
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Osinski C, McKenzie IF. MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat Med 1998;4(3):315-20
   PubMed Web of Science ®Google Scholar
• Adluri S, Gilewski T, Zhang S, et al. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. Br J Cancer 1999;79(11-12):1806-12
   PubMed Web of Science ®Google Scholar
• Gilewski T, Adluri S, Ragupathi G, et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6(5):1693-701
   PubMed Web of Science ®Google Scholar
• Musselli C, Ragupathi G, Gilewski T, et al. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer 2002;97(5):660-7
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54(3):254-64
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ueno T, Kawaoka T, et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 2005;25(5):3575-9
   PubMed Web of Science ®Google Scholar
• Sabbatini PJ, Ragupathi G, Hood C, et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 2007;13(14):4170-7
   PubMed Web of Science ®Google Scholar
• Rossmann E, Osterborg A, Lofvenberg E, et al. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study. Hum Vaccin Immunother 2014;10(11):3394-408
   PubMed Web of Science ®Google Scholar
• Palmer M, Parker J, Modi S, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin lung Cancer 2001;3(1):49-57. discussion 58
   PubMedGoogle Scholar
• North SA, Graham K, Bodnar D, Venner P. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J Urol 2006;176(1):91-5
   PubMed Web of Science ®Google Scholar
• Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23(27):6674-81
   PubMed Web of Science ®Google Scholar
• Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011;137(9):1337-42
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013;105(4):256-65
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Mitchell P, Vansteenkiste JF, et al. START2: Tecemotide in unresectable stage III NSCLC after first-line concurrent chemoradiotherapy. ASCO Meeting Abstracts 2014;32(15 Suppl):TPS7608
   Google Scholar
• PRNewswire. Merck KGaA discontinues clinical development program of tecemotide as a monotherapy in stage III non-small cell lung cancer. 2014. Available from: http://www.prnewswire.com/news-releases/merck-kgaa-discontinues-clinical-development-program-of-tecemotide-as-a-monotherapy-in-stage-iii-non-small-cell-lung-cancer-274891191.html [Last accessed 29 May 2015]
   Google Scholar
• Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 2006;8(3):R27
   PubMed Web of Science ®Google Scholar
• Vassilaros S, Tsibanis A, Tsikkinis A, et al. Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunother 2013;5(11):1177-82
   PubMed Web of Science ®Google Scholar
• Kimura T, McKolanis JR, Dzubinski LA, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 2013;6(1):18-26
   PubMed Web of Science ®Google Scholar
• Kovjazin R, Volovitz I, Kundel Y, et al. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine 2011;29(29-30):4676-86
   PubMed Web of Science ®Google Scholar
• Carmon L, Avivi I, Kovjazin R, et al. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol 2015;169(1):44-56
   PubMed Web of Science ®Google Scholar
• Singhal A, Fohn M, Hakomori S. Induction of alpha-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res 1991;51(5):1406-11
   PubMed Web of Science ®Google Scholar
• MacLean GD, Reddish M, Koganty RR, et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993;36(4):215-22
   PubMed Web of Science ®Google Scholar
• Miles DW, Towlson KE, Graham R, et al. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 1996;74(8):1292-6
   PubMed Web of Science ®Google Scholar
• Miles D, Roche H, Martin M, et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 2011;16(8):1092-100
   PubMed Web of Science ®Google Scholar
• Slovin SF, Ragupathi G, Fernandez C, et al. A polyvalent vaccine for high-risk prostate patients: “are more antigens better?”. Cancer Immunol Immunother 2007;56(12):1921-30
   PubMed Web of Science ®Google Scholar
• Scholl SM, Balloul JM, Le Goc G, et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 2000;23(5):570-80
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003;5(8):690-9
   PubMed Web of Science ®Google Scholar
• Dreicer R, Stadler WM, Ahmann FR, et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New drugs 2009;27(4):379-86
   PubMed Web of Science ®Google Scholar
• Oudard S, Rixe O, Beuselinck B, et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 2011;60(2):261-71
   PubMed Web of Science ®Google Scholar
• Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J thorac Oncol 2008;3(7):735-44
   PubMed Web of Science ®Google Scholar
• Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011;12(12):1125-33
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008;14(10):3060-9
   PubMed Web of Science ®Google Scholar
• Arlen PM, Pazdur M, Skarupa L, et al. A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin Breast Cancer 2006;7(2):176-9
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim-Schulze S, Manson K, et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med 2007;5:60
   PubMed Web of Science ®Google Scholar
• Today MN. Therion reports results of Phase 3 PANVAC-VF trial and announces plans for company sale. 2006. Available from: http://www.medicalnewstoday.com/releases/46137.php [Last accessed 29 May 2015]
   Google Scholar
• Claudepierre MC, Hortelano J, Schaedler E, et al. Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy. J Virol 2014;88(10):5242-55
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392(6673):245-52
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997;15(2):94-103
   PubMed Web of Science ®Google Scholar
• Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96(9):3102-8
   PubMed Web of Science ®Google Scholar
• Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 2002;51(11-12):669-73
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Ohta K, Kawabuchi Y, et al. Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells. Anticancer Res 2005;25(3c):2407-15
   Google Scholar
• Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004;10(14):4699-708
   PubMed Web of Science ®Google Scholar
• Loveland BE, Zhao A, White S, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12(3 Pt 1):869-77
   PubMed Web of Science ®Google Scholar
• Mitchell PL, Quinn MA, Grant PT, et al. A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer. J Immunother Cancer 2014;2:16
   PubMedGoogle Scholar
• Gray HJ, Gargosky SE. CAN-003 Study Team. Progression-free survival in ovarian cancer patients in second remission with mucin-1 autologous dendritic cell therapy. ASCO Meeting Abstracts 2014;32(15 Suppl):5504
   Google Scholar
• Berek JS, Goh JC, Gray HJ, et al. A study of autologous dendritic cell therapy targeting mucin-1 for treatment of patients with epithelial ovarian cancer in first remission. ASCO Meeting Abstracts 2012;30(15 Suppl):TPS5113
   Google Scholar
• Ltd PB. Cvac as maintenance treatment in patients with EOC in complete remission following first-line chemotherapy or second-line treatment (CANVAS). 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT01521143?term=cvac&rank=4 [Last accessed 29 May 2015]
   Google Scholar
• Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66(11):5910-18
   PubMed Web of Science ®Google Scholar
• Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994;1(9):751-61
   PubMed Web of Science ®Google Scholar
• Kondo H, Hazama S, Kawaoka T, et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res 2008;28(1B):379-87
   Google Scholar
• Morse MA, Niedzwiecki D, Marshall JL, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013;258(6):879-86
   PubMed Web of Science ®Google Scholar
• Muller MR, Grunebach F, Nencioni A, Brossart P. Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol 2003;170(12):5892-6
   PubMed Web of Science ®Google Scholar
• Rittig SM, Haentschel M, Weimer KJ, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 2011;19(5):990-9
   PubMed Web of Science ®Google Scholar
• Picco G, Beatson R, Taylor-Papadimitriou J, Burchell JM. Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas. Eur J Immunol 2014;44(7):1947-55
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, DePan C, Riley JP, et al. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 2003;170(10):5317-25
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Avivi I, Vasir B, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013;19(13):3640-8
   PubMed Web of Science ®Google Scholar
• Dobrzanski MJ, Rewers-Felkins KA, Quinlin IS, et al. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin Immunol 2009;133(3):333-52
   PubMed Web of Science ®Google Scholar
• Dobrzanski MJ, Rewers-Felkins KA, Samad KA, et al. Immunotherapy with IL-10- and IFN-gamma-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol Immunother 2012;61(6):839-54
   PubMed Web of Science ®Google Scholar
• Wilkie S, Picco G, Foster J, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 2008;180(7):4901-9
   PubMed Web of Science ®Google Scholar
• Mollick JA, Hodi FS, Soiffer RJ, et al. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun 2003;3:3
   PubMedGoogle Scholar
• Ibrahim NK, Yariz KO, Bondarenko I, et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 2011;17(21):6822-30
   PubMed Web of Science ®Google Scholar
• Wei X, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell 2006;21(2):295-305
   PubMed Web of Science ®Google Scholar
• Braun DP, Crist KA, Shaheen F, et al. Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity. Am J Surg 2005;190(4):570-1
   PubMed Web of Science ®Google Scholar
• Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol methods 2005;304(1-2):88-99
   PubMed Web of Science ®Google Scholar
• Schettini J, Kidiyoor A, Besmer DM, et al. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. Cancer Immunol Immunother 2012;61(11):2055-65
   PubMed Web of Science ®Google Scholar
• Moreno M, Bontkes HJ, Scheper RJ, et al. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer lett 2007;257(1):47-55
   PubMed Web of Science ®Google Scholar
• Reilly RM, Sandhu J, Alvarez-Diez TM, et al. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinetics 1995;28(2):126-42
   PubMed Web of Science ®Google Scholar
• Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52(12):3402-8
   PubMed Web of Science ®Google Scholar
• Pichinuk E, Benhar I, Jacobi O, et al. Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells. Cancer Res 2012;72(13):3324-36
   PubMed Web of Science ®Google Scholar
• Rubinstein DB, Karmely M, Ziv R, et al. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells. Cancer Res 2006;66(23):11247-53
   PubMed Web of Science ®Google Scholar
• Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993;68(2):403-6
   PubMed Web of Science ®Google Scholar
• Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2006;24(4):571-8
   PubMed Web of Science ®Google Scholar
• Oei AL, Verheijen RH, Seiden MV, et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer 2007;120(12):2710-14
   PubMed Web of Science ®Google Scholar
• Gulec SA, Cohen SJ, Pennington KL, et al. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial. Clin Cancer Res 2011;17(12):4091-100
   PubMed Web of Science ®Google Scholar
• Gold DV, Schutsky K, Modrak D, Cardillo TM. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res 2003;9(10 Pt 2):3929S-37S
   Google Scholar
• Ocean AJ, Pennington KL, Guarino MJ, et al. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer 2012;118(22):5497-506
   PubMed Web of Science ®Google Scholar
• DeNardo SJ, Kramer EL, O’Donnell RT, et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med 1997;38(8):1180-5
   PubMed Web of Science ®Google Scholar
• Garkavij M, Samarzija M, Ewers SB, et al. Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F(ab’)2 in patients with MUC1-positive non-small cell lung cancer. Anticancer Res 2005;25(6C):4663-71
   PubMed Web of Science ®Google Scholar
• Available from: http://www.sitcancer.org [Last accessed 29 May 2015]
   Google Scholar
• Available from: http://www.celltherapysociety.org [Last accessed 29 May 2015]
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372(21):2018-28
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372(21):2006-17
   PubMed Web of Science ®Google Scholar
• Lepisto AJ, Moser AJ, Zeh H, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008;6(B):955-64
   PubMedGoogle Scholar